Compare SKYX & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYX | NGEN |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Building Products | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.8M | 317.6M |
| IPO Year | 2022 | N/A |
| Metric | SKYX | NGEN |
|---|---|---|
| Price | $2.12 | $4.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 150.8K |
| Earning Date | 03-23-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,751,118.00 | N/A |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $26.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.06 | N/A |
| 52 Week Low | $0.88 | $1.50 |
| 52 Week High | $3.29 | $6.30 |
| Indicator | SKYX | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 33.78 |
| Support Level | $2.00 | $3.89 |
| Resistance Level | $2.63 | $4.24 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 20.25 | 47.57 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.